Top Markets
Coin of the day
Scandion Oncology A/S Scandion Oncology A/S

Scandion Oncology A/S

SCOL
Rank in Stocks #40631
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S... Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Share Price
$0.00045794
Last synced: 2025-07-11
Market Cap
$107.51K
Change (1 day)
-36.01%
Change (1 year)
0.00%
Country
DK
Trade Scandion Oncology A/S (SCOL)

Category

Number of shares outstanding for Scandion Oncology A/S (SCOL)
Number of shares outstanding as of August 2026: 0
According to Scandion Oncology A/S latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Scandion Oncology A/S (SCOL) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
- -
CH
- -
KR
0.00 -
BE